CD133 Expression in Pancreatic Cancer
Author Information
Author(s): Heike Immervoll, Dag Hoem, Per Øystein Sakariassen, Ole Johnny Steffensen, Anders Molven
Primary Institution: University of Bergen
Hypothesis
The study aims to examine the distribution of CD133 in pancreatic exocrine cancer.
Conclusion
CD133 expression in pancreatic ductal adenocarcinomas does not correlate with patient survival, but it may serve as a potential clinical marker.
Supporting Evidence
- CD133 was expressed on the apical membrane of ductal cells in the pancreas.
- In pancreatic ductal adenocarcinomas, 80% of cases showed CD133 positivity.
- There was no correlation between CD133 expression and patient survival.
Takeaway
The study looked at a protein called CD133 in pancreatic cancer cells and found it might help doctors identify cancer, but it doesn't predict how long patients will live.
Methodology
The study evaluated 51 cases of pancreatic ductal adenocarcinomas using immunohistochemistry to assess CD133 expression.
Limitations
The study did not find a correlation between CD133 expression and patient survival or tumor characteristics.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website